Brain-Derived Neurotrophic Factor (BDNF) as a Predictor of Treatment Response in Major Depressive Disorder (MDD): A Systematic Review

Int J Mol Sci. 2023 Sep 30;24(19):14810. doi: 10.3390/ijms241914810.

Abstract

Brain-derived neurotrophic factor (BDNF) has been studied as a biomarker of major depressive disorder (MDD). Besides diagnostic biomarkers, clinically useful biomarkers can inform response to treatment. We aimed to review all studies that sought to relate BDNF baseline levels, or BDNF polymorphisms, with response to treatment in MDD. In order to achieve this, we performed a systematic review of studies that explored the relation of BDNF with both pharmacological and non-pharmacological treatment. Finally, we reviewed the evidence that relates peripheral levels of BDNF and BDNF polymorphisms with the development and management of treatment-resistant depression.

Keywords: BDNF; biomarkers; major depression; major depressive disorder; neurotrophins; treatment refractoriness; treatment resistance; treatment response; treatment-resistant depression.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Biomarkers
  • Brain-Derived Neurotrophic Factor / genetics
  • Brain-Derived Neurotrophic Factor / therapeutic use
  • Depressive Disorder, Major* / diagnosis
  • Depressive Disorder, Major* / drug therapy
  • Depressive Disorder, Major* / genetics
  • Depressive Disorder, Treatment-Resistant*
  • Humans
  • Polymorphism, Genetic

Substances

  • Brain-Derived Neurotrophic Factor
  • Biomarkers